Open AccessChinese herbal medicine for hypertension complicated with hyperlipidemia
Author(s) -
Yinan Liu,
Jing Yang,
Xue Wang,
Chengkui Xiu,
Yefa Hu,
Dan Wu,
Ye Wu,
Lei Yan
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024345
Subject(s) - medicine , cochrane library , medline , traditional chinese medicine , meta analysis , adverse effect , hyperlipidemia , randomized controlled trial , intensive care medicine , clinical trial , systematic review , electronic database , alternative medicine , disease , chinese patent medicine , traditional medicine , database , pathology , diabetes mellitus , endocrinology , political science , computer science , law
Background: Hypertension combined with hyperlipidemia (HTN-HLP), as a common clinical chronic disease combination, will increase the incidence of cardiovascular and cerebrovascular diseases, increase the occurrence of sudden death and other adverse events. At present, the commonly used therapeutic drugs are mainly combined with antihypertensive drugs and lipid-lowering drugs, which not only have poor compliance, but also have adverse reactions. Currently, traditional Chinese medicine, as a traditional medicine in China, has been applied in clinical practice for thousands of years and has rich clinical experience in treating HTN-HLP. However, there is no systematic evaluation of the efficacy, safety and improvement of patients’ quality of life. This systematic review and meta-analysis will assess studies of the effects and safety of Chinese herbal medicine (CHM) for HTN-HLP patients. Methods: We will search PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science (ISI), China National Knowledge Infrastructure, Wan fang Database, Chinese Scientific Journals Full-Text Database (VIP) and China Biological Medicine Database from the time when databases were established to 01, February 2021. After a series of screening, randomized controlled trials (RCTs) will be included related to CHM for HTN-HLP. Two researchers will assess the RCTs through the Cochrane bias risk assessment tool. And the evidence grade of the results will be evaluated by GRADEprofiler software. Results: This study will provide a reliable evidence for the efficiency of antihypertensive and reducing blood lipids of CHM for HTN-HLP. Conclusion: We will summarize the methods and provide sufficient evidence to confirm the efficacy and safety of CHM for HTN-HLP. INPLASY registration number: INPLASY2020110144.